[Featured Stock] Kolon Group Shares Surge for Two Consecutive Days on 'Invossa' Clinical Trial Resumption

[Asia Economy Reporter Koo Eun-mo] Kolon affiliates have shown strong performance for two consecutive days. This is interpreted as reflecting expectations that Kolon TissueGene will escape the risk of delisting after being notified of the resumption of clinical trials in the United States for the osteoarthritis treatment 'Invossa K Injection (Invossa)'.

As of 9:16 AM on the 14th, Kolon, the major shareholder of Kolon TissueGene, was trading at 23,500 KRW, up 29.83% (5,400 KRW) compared to the previous trading day. This is a sharp rise for two consecutive days following the upper limit price the day before. At the same time, Kolon Life Science, Kolon Preferred, Kolon Material, Kolon Global, Kolon Plastic, and Kolon Global Preferred are also showing strong performance.

Earlier, Kolon TissueGene announced on the 13th that it had received an official letter from the U.S. Food and Drug Administration (FDA) on the 11th, stating that it is allowed to resume the Phase 3 clinical trial (patient dosing) of Invossa in the United States.